E
Sell
3/14/2023Downgrade
Bright Minds Biosciences Inc. (DRUG) was downgraded to E+ from D on 3/14/2023 due to a decline in the volatility index and total return index.
D
Sell
2/9/2023Upgraded
Bright Minds Biosciences Inc. (DRUG) was upgraded to D from D- on 2/9/2023 due to a major increase in the growth index, solvency index and volatility index. The quick ratio increased from 8 to 21.34, earnings per share increased from -$0.1638 to -$0.0959, and EBIT increased 27.19% from -$2.28M to -$1.66M.
D
Sell
9/21/2022Upgraded
Bright Minds Biosciences Inc. (DRUG) was upgraded to D- from E+ on 9/21/2022 due to an increase in the valuation index, total return index and volatility index.
E
Sell
9/2/2022Downgrade
Bright Minds Biosciences Inc. (DRUG) was downgraded to E+ from D- on 9/2/2022 due to a decline in the valuation index and volatility index.
D
Sell
8/18/2022Upgraded
Bright Minds Biosciences Inc. (DRUG) was upgraded to D- from E+ on 8/18/2022 due to an increase in the growth index and valuation index. Earnings per share increased from -$0.3 to -$0.1756, EBIT increased 39.88% from -$3.46M to -$2.08M, and operating cash flow increased 22.06% from -$2.88M to -$2.24M.
E
Sell
2/7/2022Downgrade
Bright Minds Biosciences Inc. (DRUG) was downgraded to E+ from D- on 2/7/2022 due to a large decline in the efficiency index, total return index and volatility index. Total capital declined 13.16% from $17.67M to $15.34M.
D
Sell
11/3/2021Upgraded
Bright Minds Biosciences Inc. (DRUG) was upgraded to D- from E on 11/3/2021 due to a noticeable increase in the volatility index, total return index and growth index.
E
Sell
8/2/2021Upgraded
Bright Minds Biosciences Inc. (DRUG) was upgraded to E from E- on 8/2/2021 due to an increase in the total return index.
E
Sell
6/2/2021None
Bright Minds Biosciences Inc. (DRUG) was downgraded to E- from U on 06/02/2021.
